Dental professionals are increasingly treating more and more medically compromised patients, due to the increase in life expectancy of the population. Among the drugs that are currently being prescribed, the antiresorptive group stands out, whose main indications are: stabilising bone loss in: osteoporosis and tumour bone metastases (breast, lung, prostate and multiple myeloma cancer). Osteonecrosis of the jaws (ONJ) in patients being treated with antiresorptive drugs (bisphosphonates, denosumab bevacizumab, sunitinib, sorafenib …) is a side effect that is causing more and more concern to our patients and oral health professionals. The key in the management of patients who take, have taken or are going to take antiresorptive drugs is to carry out PREVENTION in the dental clinic. Basic Medical Planning (BMP) should be performed prior to any dental treatment in these patients. It is crucial to know the risk factors for ONJ due to medication and more than ever, it is essential to establish a PERSONALISED oral hygiene prevention PLAN. The «stage at risk» and «stage 0» should always be considered when planning dental treatment in these patients.